Colostrum and Lactoferrin Protect against Side Effects of Therapy with Antibiotics, Anti-inflammatory Drugs and Steroids, and Psychophysical Stress: A Comprehensive Review.
Jolanta ArtymMichał ZimeckiPublished in: Biomedicines (2023)
In this article, we review the benefits of applying bovine colostrum (BC) and lactoferrin (LF) in animal models and clinical trials that include corticosteroid application and psychic stress, treatment with non-steroid anti-inflammatory drugs (NSAIDs) and antibiotics. A majority of the reported investigations were performed with native bovine or recombinant human LF, applied alone or in combination with probiotics, as nutraceutics and diet supplements. Apart from reducing adverse side effects of the applied therapeutics, BC and LF augmented their efficacy and improved the wellness of patients. In conclusion, LF and complete native colostrum, preferably administered with probiotic bacteria, are highly recommended for inclusion in therapeutic protocols in NSAIDs and corticosteroid anti-inflammatory, as well as antibiotic, therapies. These colostrum-based products can also be of value for individuals subjected to prolonged psychophysical stress (mediated by endogenous corticosteroids), especially at high ambient temperatures (soldiers and emergency services), as well as physically active people and training athletes. They are also recommended for patients during recovery from trauma and surgery, which are always associated with severe psychophysical stress.
Keyphrases
- anti inflammatory drugs
- end stage renal disease
- clinical trial
- ejection fraction
- recombinant human
- newly diagnosed
- healthcare
- emergency department
- chronic kidney disease
- human milk
- public health
- patient reported outcomes
- primary care
- minimally invasive
- randomized controlled trial
- air pollution
- anti inflammatory
- peritoneal dialysis
- coronary artery disease
- small molecule
- coronary artery bypass
- stress induced
- bone marrow
- atrial fibrillation
- patient reported
- early onset
- mesenchymal stem cells
- phase ii
- acute coronary syndrome
- weight loss
- health insurance
- virtual reality